1. Home
  2. BGI vs LSTA Comparison

BGI vs LSTA Comparison

Compare BGI & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Birks Group Inc.

BGI

Birks Group Inc.

N/A

Current Price

$1.09

Market Cap

22.7M

Sector

N/A

ML Signal

N/A

Logo Lisata Therapeutics Inc.

LSTA

Lisata Therapeutics Inc.

HOLD

Current Price

$1.95

Market Cap

20.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BGI
LSTA
Founded
1879
1980
Country
Canada
United States
Employees
N/A
N/A
Industry
Misc Health and Biotechnology Services
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
22.7M
20.9M
IPO Year
2005
N/A

Fundamental Metrics

Financial Performance
Metric
BGI
LSTA
Price
$1.09
$1.95
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$23.50
AVG Volume (30 Days)
23.7K
27.3K
Earning Date
12-05-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$136,846,182.00
$1,070,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
7.45
N/A
52 Week Low
$0.56
$1.81
52 Week High
$2.03
$4.20

Technical Indicators

Market Signals
Indicator
BGI
LSTA
Relative Strength Index (RSI) 57.44 38.85
Support Level $1.00 $1.85
Resistance Level $1.11 $2.09
Average True Range (ATR) 0.04 0.15
MACD 0.00 0.01
Stochastic Oscillator 93.34 36.81

Price Performance

Historical Comparison
BGI
LSTA

About BGI Birks Group Inc.

Birks Group Inc is a part of the leisure industry. The company designs, develops, produces, and retails fine jewelry, timepieces, and gifts. Its operating segments include Retail and Other. The company generates maximum revenue from the Retail segment. Its retail segment consists of retail operations whereby it operates stores in Canada under the Maison Birks, Brinkhaus, Graff, and Patek Phillippe brands. The other segment consists mainly of wholesale business, e-commerce business, and gold exchange business.

About LSTA Lisata Therapeutics Inc.

Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The group has one operating segment, the research and development of its investigational drug product.

Share on Social Networks: